Wu, Z., Cai, J., Chen, J., et al. (2014) Autologous Bone Marrow Mononuclear Cell Infusion and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus: An Open-Label, Randomized Controlled Clinical Trial. Cytotherapy, 16, 258-265.
http://dx.doi.org/10.1016/j.jcyt.2013.10.004

has been cited by the following article:

• TITLE: Use of Human Embryonic Stem Cells in the Treatment of Diabetes Mellitus: A Case Series

  AUTHORS: Geeta Shroff

  KEYWORDS: Diabetes, hESC Therapy, iPSCs

  JOURNAL NAME: Journal of Diabetes Mellitus, Vol.5 No.4, November 23, 2015

  ABSTRACT: Introduction: Diabetes mellitus (DM), a metabolic disorder, is known to be highly prevalent in people aged 40 - 60 years in developing countries whereas in developed countries, it mostly affects people above the age of 60 years. It is of two types: DM type I, an autoimmune disorder that mostly onsets after an infection and DM type II that is commonly associated with obesity. Several treatments are available for the treatment of DM, but none has successfully cured diabetes. Nowadays, stem cell therapy is being investigated for use in the treatment of DM and has shown positive results. Case Report: Our study presented results of three diabetic patients who were treated with human embryonic stem cell (hESC) therapy. Following the therapy, blood glucose levels were reduced. An improvement was observed in eye sight, stamina, gait pattern endurance, mental focus ability and muscle strength. There was a reduction in secondary side effects of high blood sugar such as affectation of cardiac, kidneys, polyneuropathy, vision etc. No adverse events and teratoma formation were observed after the treatment. Conclusion: It was concluded that hESCs showed good therapeutic potential in the treatment of patients with diabetes.